Picture of RenovaCare logo

RCAR RenovaCare Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+9636.28%
3m+9178.01%
6m-14.83%
1yr-99.94%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-99.97%
50d MA-99.75%
200d MA-99.85%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-568.91%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of RenovaCare EPS forecast chart

Profile Summary

RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company’s CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
June 10th, 1997
Public Since
August 8th, 2000
No. of Shareholders
362
No. of Employees
1
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
87,352,364

RCAR Share Price Performance

Upcoming Events for RCAR

Similar to RCAR

Picture of Actavia Life Sciences logo

Actavia Life Sciences

us flag iconPink Sheets on Nasdaq

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Ramoil Management logo

Ramoil Management

us flag iconPink Sheets on Nasdaq

Picture of Adynxx logo

Adynxx

us flag iconPink Sheets on Nasdaq

FAQ